Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -142.9%. (1997–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $555507 | $1M | $4M | $34M | $62M | $172M | $196M | $42M | $138M | $117M | $203M |
| Enterprise Value | $-4134233 | $-3213800 | $-387508 | $29M | $49M | $156M | $187M | $32M | $135M | $111M | $202M |
| P/E Ratio → | -0.07 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 108.74 | 586.05 | 297.89 | 63.86 | 599.87 | 783.65 | 518.03 |
| P/B Ratio | 0.10 | 0.30 | 0.87 | 5.86 | 4.15 | 10.15 | 21.13 | 4.48 | 59.91 | 19.44 | 341.13 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 85.53 | 530.50 | 282.99 | 49.31 | 587.39 | 742.66 | 515.38 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | -1242674.4% | -1661027.2% | -787423.3% |
| Operating Margin | — | — | — | — | -2072.0% | -3542.5% | -1197.3% | -912.0% | -2612.5% | -3228.7% | -1555.3% |
| Net Profit Margin | — | — | — | — | -2094.9% | -3540.9% | -1196.6% | -980.3% | -2697.9% | -3796.2% | -1855.8% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -142.9% | -142.9% | -245.9% | -117.2% | -75.1% | -79.3% | -84.9% | -110.1% | -148.7% | -171.4% | -693.7% |
| ROA | -104.5% | -104.5% | -171.6% | -94.8% | -65.2% | -69.2% | -74.9% | -87.9% | -108.0% | -125.1% | -339.8% |
| ROIC | -2334.9% | -2334.9% | -911.8% | -630.8% | -747.2% | -12703.3% | — | — | — | — | — |
| ROCE | -141.0% | -141.0% | -157.3% | -112.7% | -70.8% | -77.5% | -84.8% | -102.1% | -130.8% | -120.9% | -387.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.13 | 0.16 | 0.08 | 0.04 | 0.00 | 0.02 | 0.42 | 0.14 | 0.87 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.96 | -0.95 | -0.78 | -0.88 | -0.96 | -1.06 | -1.02 | -1.25 | -1.02 | -1.75 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -496.60 | -496.60 | -1323.37 | — | — | — | -4994.62 | -109.34 | -27.21 | -14.76 | -23.01 |
Net cash position: cash ($5M) exceeds total debt ($336718)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.85 | 3.85 | 3.13 | 3.40 | 10.03 | 9.95 | 7.53 | 9.40 | 2.21 | 15.13 | 2.61 |
| Quick Ratio | 3.85 | 3.85 | 3.13 | 3.40 | 10.03 | 9.95 | 7.53 | 9.40 | 2.21 | 15.13 | 2.61 |
| Cash Ratio | 3.47 | 3.47 | 2.90 | 2.97 | 9.66 | 9.36 | 7.17 | 9.00 | 2.10 | 14.59 | 2.55 |
| Asset Turnover | — | — | — | — | 0.03 | 0.02 | 0.06 | 0.06 | 0.06 | 0.02 | 0.23 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 158.78 | 82.56 | 116.05 | — | 182.50 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.2% |
| Shares Outstanding | — | $673945 | $156084 | $251300 | $205400 | $147600 | $120900 | $34148 | $12083 | $8211 | $5176 |
Capital exhaustion and dilution
As reported in financial statements, AEMD's ROIC has remained consistently negative over the last ten quarters, bottoming out at -194.8% in 2024Q4, which underscores the company's inability to generate productive returns on the capital deployed into its clinical-stage research and development initiatives.
The deeply negative ROIC figures reflect a business model that consumes capital without achieving the commercial milestones necessary to generate a return. Investors should interpret these trends as evidence of structural value destruction, as the company continues to fund high-cost clinical trials without a clear path to operational profitability.
According to recent SEC filings, AEMD's current ratio has fluctuated significantly, dropping from 4.49 in 2025Q1 to 3.85 by 2026Q4, which suggests that while the company maintains a nominal liquidity cushion, its ability to sustain operations under stress is rapidly diminishing due to persistent cash burn.
The reliance on current assets to cover ongoing clinical expenses creates a precarious liquidity profile that leaves little room for operational delays. The lack of revenue means that any disruption in the company's ability to raise external capital would likely lead to an immediate liquidity crisis.
Based on AEMD's reported figures, the debt-to-equity ratio remains low, peaking at 0.20 in 2026Q1, yet this metric fails to capture the significant financial risk posed by the company's reliance on frequent equity issuance to fund its ongoing research and development activities.
While the low debt levels might appear favorable in isolation, they are a byproduct of the company's inability to access traditional credit markets rather than a sign of financial strength. The true leverage risk is found in the dilution of existing shareholders, which is the primary mechanism for financing the company's survival.
As indicated by market data, the price-to-book ratio of 0.12 is frequently misapplied to AEMD, as it obscures the reality that the company's book value is largely composed of intangible assets and R&D spending that may hold little liquidation value in a distressed scenario.
Investors should avoid using P/B as a valuation floor, as it fails to account for the high probability of further equity dilution that will continue to erode the per-share book value. A more appropriate focus would be the 'cash runway to milestone' metric, which better reflects the company's actual operational viability.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AEMD stock.
Aethlon Medical, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Aethlon Medical, Inc.'s return on equity (ROE) is -142.9%. The historical average is -153.9%.
Based on historical data, Aethlon Medical, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.